Soares Sara, Roque Fátima, Teixeira Rodrigues António, Figueiras Adolfo, Herdeiro Maria Teresa
Institute for Research in Biomedicine - iBiMED & Health Sciences Program, University of Aveiro, Campus Universitário de Santiago, Aveiro, Portugal.
Institute for Research in Biomedicine - iBiMED & Health Sciences Program, University of Aveiro, Campus Universitário de Santiago, Aveiro, Portugal; Research Unit for Inland Development, Polytechnic of Guarda (Unidade de Investigação para o Desenvolvimento do Interior - UDI/IPG), Guarda, Portugal.
Clin Ther. 2015 Sep;37(9):2122-8. doi: 10.1016/j.clinthera.2015.07.015. Epub 2015 Aug 6.
The information that is available when marketing authorizations are approved is limited. Pharmacovigilance has an important role during the postauthorization period, and alerts published by national authorities allow health care professionals to be informed about new data on safety profiles. This study therefore sought to analyze all safety alerts published by the Portuguese National Authority of Medicines and Health Products I.P. (INFARMED).
We conducted an observational study of all alerts published on the INFARMED website from January 2002 through December 2014. From the data included in the alerts, the following information was abstracted: active substance name (and trade name), event that led to the alert, and the resulting safety measures. Active substances were classified according to the Anatomical Therapeutic Chemical (ATC) code.
A total of 562 alerts were published, and 304 were eligible for inclusion. The musculoskeletal system was the ATC code with more alerts (n = 53), followed by the nervous system (n = 42). Communication of the information and recommendations to the health care professionals and the public in general was the most frequent safety measure (n = 128), followed by changes in the Summary of the Product Characteristics and package information leaflet (n = 66). During the study period, 26 marketing authorizations were temporarily suspended and 10 were revoked.
The knowledge of the alerts published during the postmarketing period is very useful to the health care professionals for improving prescription and use of medicines and to the scientific community for the development of new researches.
药品上市许可获批时可获取的信息有限。药物警戒在上市后阶段发挥着重要作用,国家当局发布的警示能让医疗保健专业人员了解安全性概况的新数据。因此,本研究旨在分析葡萄牙药品和健康产品国家局(INFARMED)发布的所有安全警示。
我们对2002年1月至2014年12月期间在INFARMED网站上发布的所有警示进行了观察性研究。从警示中包含的数据中,提取了以下信息:活性物质名称(及商品名)、引发警示的事件以及由此产生的安全措施。活性物质根据解剖治疗学化学(ATC)代码进行分类。
共发布了562条警示,其中304条符合纳入标准。肌肉骨骼系统是产生警示最多的ATC代码(n = 53),其次是神经系统(n = 42)。向医疗保健专业人员和公众传达信息及建议是最常见的安全措施(n = 128),其次是产品特性摘要和包装说明书的变更(n = 66)。在研究期间,26项上市许可被暂时中止,10项被撤销。
了解上市后阶段发布的警示对医疗保健专业人员改善药品处方和使用以及科学界开展新研究非常有用。